International Workshop on NASH Biomarkers 2016

Slideset

Viral Hepatitis and Liver Disease

Methods of MR fat quantification and their pros and cons | Michael Middleton, MD, PhD

Slideset

Viral Hepatitis and Liver Disease

Noninvasive imaging methods for assessment of liver damage in NASH | Bachir Taouli, MD

Slideset

Viral Hepatitis and Liver Disease

NASH and Fibroscan | Raj Vuppalanchi, MD

Slideset

Viral Hepatitis and Liver Disease

O_04 - Blood-based Protein Biomarkers of NASH | Dr. S. Williams

Slideset

Viral Hepatitis and Liver Disease

O_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease | Dr. P. Eddowes

Slideset

Viral Hepatitis and Liver Disease

LiverMultiScan – quantitative MR imaging for NASH | Rajarshi Banerjee

Slideset

Viral Hepatitis and Liver Disease

O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. Sanyal

Slideset

Viral Hepatitis and Liver Disease

Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MD

Slideset

Viral Hepatitis and Liver Disease

Principles of Biomarker Development | Margery Connelly, PhD, MBA

Slideset

Viral Hepatitis and Liver Disease

Quantitative measures of liver health | Grey Everson, MD

Slideset

Viral Hepatitis and Liver Disease

Defining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBS

Slideset

Viral Hepatitis and Liver Disease

O_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study | Dr. P. Eddowes

Slideset

Viral Hepatitis and Liver Disease

Biomarkers: what can be learned from type 2 diabetes | Manu Chakravarthy, MD, PhD

Slideset

Viral Hepatitis and Liver Disease

Proteomics-based biomarker discovery in NAFLD | Naga Chalasani, MD

Slideset

Viral Hepatitis and Liver Disease

Study Design and endpoints in Omics-based biomarker studies | Stephen Williams, MD, PhD

Slideset

Viral Hepatitis and Liver Disease

Lipid and Bile acids as NAFLD-related biomarkers | Puneet Puri, MBBS, MD

Slideset

Viral Hepatitis and Liver Disease

Potential approach to identify the NAFLD patient who will develop HCC | Yujin Hoshida, MD, PhD

Slideset

Viral Hepatitis and Liver Disease

Simple laboratory based indices | Ray Kim, MD

Slideset

Viral Hepatitis and Liver Disease

Biomarker development in pediatric NAFLD: special challenges in a special population | Saul Karpen, MD, PhD

Slideset

Viral Hepatitis and Liver Disease

Dynamic measurement of physiologic functions: any role in NASH diagnostics | Stephen Previs, MD

Slideset

Viral Hepatitis and Liver Disease

Microbiome: diagnostic considerations | Patrick Gillevet

Slideset

Viral Hepatitis and Liver Disease

International Workshop on NASH Biomarkers 2016

Methods of MR fat quantification and their pros and cons | Michael Middleton, MD, PhD

Noninvasive imaging methods for assessment of liver damage in NASH | Bachir Taouli, MD

NASH and Fibroscan | Raj Vuppalanchi, MD

O_04 - Blood-based Protein Biomarkers of NASH | Dr. S. Williams

O_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease | Dr. P. Eddowes

LiverMultiScan – quantitative MR imaging for NASH | Rajarshi Banerjee

O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. Sanyal

Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MD

Principles of Biomarker Development | Margery Connelly, PhD, MBA

Quantitative measures of liver health | Grey Everson, MD

Defining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBS

O_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study | Dr. P. Eddowes

Biomarkers: what can be learned from type 2 diabetes | Manu Chakravarthy, MD, PhD

Proteomics-based biomarker discovery in NAFLD | Naga Chalasani, MD

Study Design and endpoints in Omics-based biomarker studies | Stephen Williams, MD, PhD

Lipid and Bile acids as NAFLD-related biomarkers | Puneet Puri, MBBS, MD

Potential approach to identify the NAFLD patient who will develop HCC | Yujin Hoshida, MD, PhD

Simple laboratory based indices | Ray Kim, MD

Biomarker development in pediatric NAFLD: special challenges in a special population | Saul Karpen, MD, PhD

Dynamic measurement of physiologic functions: any role in NASH diagnostics | Stephen Previs, MD

Microbiome: diagnostic considerations | Patrick Gillevet

O_03 - A non-invasive lipidomic test accurately discriminates NASH from steatosis: a blind validation study | Dr. T. Montgomery